Ocumetics Technology Corp. (TSXV: OTC; OTCQB: OTCFF; FRA: 2QBO), a developer of next-generation vision technology, announced highly encouraging six-month postoperative results from the first group of patients in its first-in-human (FIH) clinical study of the Ocumetics Accommodating Intraocular Lens. The results demonstrate that patients achieved clinical outcomes meeting or exceeding the company's expectations, with all patients continuing to experience vision improvements and a strong safety profile.
Patients in Group One entered the study with severely impaired vision, including one individual considered legally blind. Six months after surgery, patients have shown improved vision and stable visual acuity, along with real-world transformations in daily life. According to the company, patients are now able to read, drive, and live independently again.
"After six months, what stands out most is not just the clinical performance of the Ocumetics Lens, but the profound impact on patients' quality of life," said Dean Burns, President and CEO of Ocumetics. "Patients who entered this study with severely impaired vision are now reading, driving, and living independently again. We're developing a technology that dramatically improves people's quality of life and we couldn't be happier."
The results reinforce the expected performance of Ocumetics' inaugural accommodating intraocular lens, which is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the need for glasses or contact lenses. The company continues to leverage surgeon feedback and patient experience into ongoing product enhancements. Updated lens refinements are currently in manufacturing and testing, supporting the planned initiation of Group Two surgeries.
"The measurable improvements in visual acuity and consistency we are seeing at six months give us tremendous confidence as we advance to the next phase of our clinical program," added Burns. "We are not only validating our technology, we are demonstrating its real-world impact. Our focus now is to build on this success, further optimize performance, and bring this life changing solution to more patients."
Ocumetics expects to initiate Group Two surgeries following completion of lens testing. The company will host a webinar on April 22, 2026, at 4:00 PM ET to discuss the six-month study results and provide updates on the FIH study. Registration is available at www.ocumetics.com/webinar.
These developments mark significant progress for Ocumetics as it advances its mission to transform vision correction through innovation. The company's technology has the potential to eliminate the need for corrective lenses, offering a life-changing solution for patients with poor vision. For further information, visit the original release on www.newmediawire.com.
